Economic implications of treatment-resistant depression among employees

PharmacoEconomics

Volumn 22, Issue 6, 2004, Pages 363-373

  Greenberg, Paul ^a   Corey Lisle, Patricia K ^b,d   Birnbaum, Howard ^a   Marynchenko, Maryna ^a   Claxton, Ami ^c,d  

^a ANALYSIS GROUP   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Pharmaceutical Product Development   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALGORITHM; ARTICLE; BEHAVIORAL RESEARCH; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEPRESSION; EMPLOYEE; EMPLOYER; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; ILLNESS BEHAVIOR; MALE; MEDICAL AUDIT; MEDICAL CARE; PERSONNEL MANAGEMENT; PRIORITY JOURNAL;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; TREATMENT FAILURE; UNITED STATES;

EID: 2342606503     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422060-00003     Document Type: Article

References (32)

1. Hirschfeld RMA, Montgomery SA, Keller MB, et al. Social functioning in depression: a review. J Clin Psychiatry 2000; 61 (4): 268-75
2. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405-18
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
4. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8-191
5. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157 (4): 1-45
6. Greenberg PE, Leong SA, Birnbaum HG. Cost of depression: current assessment and future directions. Exp Rev Pharmacoeconomics Outcomes Res 2001; 1 (1): 69-76
7. Mitchell J, Greenberg J, Finch K, et al. Effectiveness and economic impact of antidepressant medications: a review. Am J Manag Care 1997; 3 (2): 323-30
8. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relationship to costs of care. Am J Manag Care 1996; 2: 1239-46
9. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16 (4): 715-30
10. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 153-62
11. American Psychiatric Association. Depression [online]. Available from URL: http://www.psych.org/public_info/depression.cfm [Accessed 2001 Jan 8]
12. Sourey D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9 (1-2): 83-91
13. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998; 59 Suppl. 20: 73-84
14. Thase ME, Friedman ES, Howland RH. Venlafaxine and treatment-resistant depression. Depress Anxiety 2000; 12 Suppl. 1: 55-62
15. Dyck MJ. Treatment-resistant depression: a critique of current approaches. Aust N Z J Psychiatry 1994; 28: 34-41
16. Rosenbaum JF, Fava M, Nierenberg AA, et al. Treatment-resistant mood disorders. In: Gabbard GO, editor. Treatment of psychiatric disorders. 3rd ed. Washington, DC: American Psychiatric Press, 2003: 1307-88
17. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York. (NY): Raven Press Ltd, 1995: 1081-97
18. Nierenberg AA, DeCecco L. Definitions of antidepressant treatment response, remission, nonresponse, partial response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 5-9
19. Sackheim HA. The definition of treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 10-7
20. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann 1998; 28 (11): 633-40
21. Corey-Lisle PK, Birnbaum H, Greenberg PE, et al. Identification of claims data 'signature' and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002; 63: 717-26
22. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 26-31
23. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19 (2): 179-98
24. Thase M. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 2002; 63 (2): 95-103
25. Austin M, Souza F, Goodwin G. Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. Br J Psychiatry 1991; 159: 510-4
26. Nierenberg A, Feighner J, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994; 14 (6): 419-23
27. Sackeim H, Rush A, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001; 25 (5): 713-28
28. Rost K, Smith R, Matthew DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3: 333-7
29. Browne RA, Melfi CA, Croghan TW, et al. Data analysis issues to consider when conducting research using physician-reported antidepressant claims. Drug Benefit Trends 1998, 33-42
30. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 18-25
31. Burton WN, Conti DJ. Use of an integrated health data warehouse to measure the employer costs of five chronic disease states. Dis Manag Health Outcomes 1998; 2 (1): 17-26
32. Barnett A, Birnbaum H, Cremieux PY, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000; 6 (11): 1243-51